There might be a promising disease for Alzheimer’s among patients of rheumatoid arthritis as there is built-in protection in them against the disease.

There is a role played by the protein GM-CSF in something that leads to the arthritic disorder and it is the defective immune system response.

There is a positive point of this as well as the immune system is marshaled that enables removal of harmful deposits in the brain that are linked to the brain disease.

The protein was able to reverse Alzheimer’s symptoms in tests on mice in about 20 days.

Following this there is a hope among scientists that a practical new treatment for the brain disease might take place.

For boosting the immune systems in cancer patients, a laboratory-made version of GM-CSF called Leukine has been used. This is being done because the safety profile is well known and these aspects of it can now turn it into a therapy for Alzheimer’s.

There is a pilot trial that is being planned by the US scientists, from the Health Byrd Alzheimer's Institute at Florida State University, for testing the theory.

Alzheimer’s sufferers will be administered the protein and it will be figured out if their symptoms improve.

Lead researcher Professor Huntington Potter said, "Our study, along with the drug's track record for safety, suggests Leukine should be tested in humans as a potential treatment for Alzheimer's disease."